Shanghai Pharmaceuticals Holding (601607.SH): Cefotaxime Sodium for Injection and Amoxicillin for Injection Pass Generic Drug Consistency Evaluation.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary Shanghai Shang Yao Xin Ya Pharmaceutical Co., Ltd. (hereinafter referred to as "Shang Yao Xin Ya") has received the "Drug Supplementary Application Approval Notice" (Notice numbers: 2025B05069, 2025B05110, 2025B05111) issued by the National Medical Products Administration (hereinafter referred to as "NMPA") for injection cefoperazone sodium and injection amikacin. The aforementioned drugs have passed the evaluation of generic drug quality and efficacy consistency. Injection cefoperazone sodium is indicated for the treatment of infections caused by specific microbial strains in the following diseases: respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, septicemia, meningitis, gonorrhea, bone and joint infections, and postpartum and gynecological infections. Injection amikacin is indicated for the treatment of infections caused by sensitive gram-negative bacteria: urinary tract (complex and simple), lower respiratory tract infections, septicemia, skin and skin structure infections, intra-abdominal infections, and gynecological infections.